Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

BACKGROUND: S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kurokawa, Y, Sugimoto, N, Miwa, H, Tsuda, M, Nishina, S, Okuda, H, Imamura, H, Gamoh, M, Sakai, D, Shimokawa, T, Komatsu, Y, Doki, Y, Tsujinaka, T, Furukawa, H
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950868/
https://ncbi.nlm.nih.gov/pubmed/24473399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.18
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky